• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Oncolytic adenovirus for treatment of malignant ascites.

作者信息

Hemminki Akseli, Heiniö Camilla

机构信息

Cancer Gene Therapy Group, Translational Immunology Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

TILT Biotherapeutics, Ltd., Helsinki, Finland.

出版信息

Mol Ther Oncolytics. 2022 Aug 14;26:302-303. doi: 10.1016/j.omto.2022.07.010. eCollection 2022 Sep 15.

DOI:10.1016/j.omto.2022.07.010
PMID:36032634
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9399406/
Abstract
摘要

相似文献

1
Oncolytic adenovirus for treatment of malignant ascites.溶瘤腺病毒治疗恶性腹水
Mol Ther Oncolytics. 2022 Aug 14;26:302-303. doi: 10.1016/j.omto.2022.07.010. eCollection 2022 Sep 15.
2
Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment.溶瘤腺病毒通过重编程腹水免疫微环境抑制晚期卵巢癌的恶性腹水。
Mol Ther Oncolytics. 2021 Nov 11;23:488-500. doi: 10.1016/j.omto.2021.11.008. eCollection 2021 Dec 17.
3
Oncolytic virus as an agent for the treatment of malignant ascites.溶瘤病毒作为治疗恶性腹水的一种药物。
Cancer Biother Radiopharm. 2009 Feb;24(1):99-102. doi: 10.1089/cbr.2008.0559.
4
Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response.恶性腹水患者的腹腔内溶瘤病毒疗法：临床疗效和抗肿瘤免疫反应的特征
Mol Ther Oncolytics. 2022 Mar 15;25:31-42. doi: 10.1016/j.omto.2022.03.003. eCollection 2022 Jun 16.
5
Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.纤维修饰、中期因子启动子调控的溶瘤腺病毒增强人恶性间皮瘤的抗肿瘤疗效。
Cancer Sci. 2013 Nov;104(11):1433-9. doi: 10.1111/cas.12267. Epub 2013 Sep 23.
6
Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation.DNA疫苗与表达GM-CSF和TGF-β2的短发夹RNA的溶瘤腺病毒联合进行的初免-加强免疫可诱导抗肿瘤免疫激活。
Oncotarget. 2017 Feb 28;8(9):15858-15877. doi: 10.18632/oncotarget.15008.
7
Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma.用于治疗恶性胶质瘤的溶瘤腺病毒的临床前及临床开发
Oncolytic Virother. 2019 Oct 24;8:27-37. doi: 10.2147/OV.S196403. eCollection 2019.
8
The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer.溶瘤腺病毒治疗在过去和未来的发展——以胰腺癌为例。
Curr Cancer Drug Targets. 2018;18(2):153-161. doi: 10.2174/1568009617666170222123925.
9
Oncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer Ascites.携带溶瘤腺病毒的月经血干细胞克服了卵巢癌腹水对病毒活性的抑制作用。
Mol Ther Oncolytics. 2017 Jun 16;6:31-44. doi: 10.1016/j.omto.2017.06.002. eCollection 2017 Sep 15.
10
A hypoxia- and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma.缺氧和端粒酶反应性溶瘤腺病毒表达可分泌的三聚体 TRAIL 触发肿瘤特异性细胞凋亡，并促进 TRAIL 耐药性脑胶质瘤中的病毒扩散。
Sci Rep. 2018 Jan 23;8(1):1420. doi: 10.1038/s41598-018-19300-6.

本文引用的文献

1
Immune response in colorectal carcinoma: a review of its significance as a predictive and prognostic biomarker.结直肠癌中的免疫反应：作为预测和预后生物标志物的意义综述。
Histopathology. 2022 Dec;81(6):696-714. doi: 10.1111/his.14713. Epub 2022 Jul 15.
2
Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response.恶性腹水患者的腹腔内溶瘤病毒疗法：临床疗效和抗肿瘤免疫反应的特征
Mol Ther Oncolytics. 2022 Mar 15;25:31-42. doi: 10.1016/j.omto.2022.03.003. eCollection 2022 Jun 16.
3
Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial.肿瘤选择性腺病毒 enadenotucirev 联合或不联合紫杉醇治疗铂耐药卵巢癌的安全性和有效性：一项 1 期临床试验。
J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003645.
4
Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes.Ad5/3 能够通过与红细胞和淋巴细胞结合来避免中和作用。
Cancer Gene Ther. 2021 May;28(5):442-454. doi: 10.1038/s41417-020-00226-z. Epub 2020 Sep 12.
5
Oncolytic viruses for cancer immunotherapy.溶瘤病毒在癌症免疫治疗中的应用。
J Hematol Oncol. 2020 Jun 29;13(1):84. doi: 10.1186/s13045-020-00922-1.
6
Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors.用于增强实体瘤T细胞疗法的临床相关溶瘤病毒平台的比较
Mol Ther Oncolytics. 2020 Mar 19;17:47-60. doi: 10.1016/j.omto.2020.03.003. eCollection 2020 Jun 26.
7
TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling.TNFa 和 IL2 编码溶瘤腺病毒激活病原体和危险相关免疫信号。
Cells. 2020 Mar 26;9(4):798. doi: 10.3390/cells9040798.
8
Challenges in liver cancer and possible treatment approaches.肝癌的挑战与可能的治疗方法。
Biochim Biophys Acta Rev Cancer. 2020 Jan;1873(1):188314. doi: 10.1016/j.bbcan.2019.188314. Epub 2019 Nov 1.
9
Prognostic significance of malignant ascites in gastric cancer patients with peritoneal metastasis: A systemic review and meta-analysis.胃癌腹膜转移患者恶性腹水的预后意义：一项系统评价与荟萃分析。
World J Clin Cases. 2019 Oct 26;7(20):3247-3258. doi: 10.12998/wjcc.v7.i20.3247.
10
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.细胞因子武装的溶瘤腺病毒在未注射肿瘤中产生的远隔效应。
Mol Ther Oncolytics. 2018 Nov 6;11:109-121. doi: 10.1016/j.omto.2018.10.005. eCollection 2018 Dec 21.